Therefore, inhibiting CNDP2 may disrupt the redox balance and sensitize tumor cells to oxidative stress, which is a rational strategy for cancer therapy; however, the established inhibitor BES is limited by poor selectivity and suboptimal drug-like properties. This evidence concerns the gene CNDP2 and cancer.